Phase 3 N=742 A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
Asthma
Primary: Total Number of Asthma Exacerbations — 36; 61 Exacerbations
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,076 Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Progression-free Survival — 8.6; 8.2 Months
Phase 3 N=1,199 Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
Castration-Resistant Prostate Cancer
Primary: Overall Survival — 18.4; 13.6 Months — p=<0.0001
Phase 3 N=132 Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Diabetes Mellitus, Type 1
Primary: Mean of Last Five 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Day 2 for Insulin Lispro 2D and Day 6 for Insulin Aspart 6D Pump…
Phase 3 N=813 A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
Major Depressive Disorder · MDD · Depression
Primary: Frequency of Patients Experiencing at Least One Adverse Event (AE) — 82.4; 84.6 percentage of participants analyzed
Phase 3 N=696 A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
Major Depressive Disorder
Primary: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment. — -11.6; -12.2; -12.2; -12.7 units on a scale — p=1.000
Phase 3 N=49 Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Treatment-emergent Adverse Events — 148; 139; 126 adverse events
Phase 3 N=55 Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Agammaglobulinemia · IgG Deficiency · Common Variable Immunodeficiency
Primary: The Proportion of Infusions With One or More Temporally-associated Adverse Events (AEs). — 0.073; 0.141; 0.150 Proportion of infusions
Phase 3 N=133 Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Diabetes Mellitus, Type 1
Primary: Mean of Last Six 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Insulin Aspart 6D Pump Reservoir In-use — 8.83; 8.43 millimoles per…
Phase 3 N=70 Iloprost Power 15 in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883
Phase 3 N=234 Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks — -0.25; -0.84 Percentage — p=0.0005
Phase 3 N=65 An Implantable Spinal Cord Stimulation Pain Management System
Chronic Pain · Pain, Intractable · Pain
Primary: Change in Visual Analog Scale (VAS) Score From Baseline to 2 Week Post Initial Fitting. — 35 participants with > 50% VAS improvement
Phase 3 N=626 Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
Carcinoma, Renal Cell · Kidney Neoplasms
Primary: Overall Survival (OS) — 7.3; 10.9; 8.4 months — p=0.0252
Phase 3 N=613 Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose — 112.9; 113.36; 101.28 percent of baseline
Phase 3 N=1,293 Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease
Primary: Pre-dose Forced Expiratory Volume in One Second (FEV1) — 104.6; 101.5 percentage of Baseline